---
title: "Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1"
id: "medrxiv-10-characterization-of-the-neoprotein-muc1-fs-in-patient-derived-cells-with-adtkd"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-characterization-of-the-neoprotein-muc1-fs-in-patient-derived-cells-with-adtkd"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.16.26363125v1?rss=1"
published_at: "2026-09-16T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-characterization-of-the-neoprotein-muc1-fs-in-patient-derived-cells-with-adtkd
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.16.26363125v1?rss=1)
- **Published At:** 2026-09-16T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Autosomal dominant tubulointerstitial kidney disease (**ADTKD**) is genetically heterogeneous and commonly causes kidney failure in mid-adulthood. - In the ADTKD subtype caused by MUC1 mutations (**ADTKD-MUC1**), a frameshift mutation produces a pathogenic neoprotein termed **MUC1-fs** that accumulates in distal renal tubular cells. - The mechanisms regulating **MUC1-fs** and the disease pathomechanism remain incompletely understood. - Researchers established primary tubular cell lines from urine of multiple affected probands and subsequently immortalized these cells for study. - Long-range sequencing was used to precisely determine the repeat region lengths of both MUC1 alleles and to localize the mutated repeat. - The pathogenic **MUC1-fs** protein is readily detectable in patient-derived tubular cells and shows a considerably longer half-life compared with wild-type **mucin 1**. - Treatment of patient-derived cells with the compound **BRD4780**, previously reported as putatively therapeutic, reduced levels of **MUC1-fs** across the cell models. - BRD4780 also affected wild-type **mucin 1** and multiple other transcriptional pathways, indicating a lack of selectivity. - Urine-derived tubular cells provide a patient-specific in vitro model suitable for analysis of **MUC1-fs** biology and for pharmacological screening of potential therapies. - Data generated in this study are available in GEO under accession GSE306788. - Ethical approval was obtained from the Ethics committee of Friedrich-Alexander University Erlangen-Nuremberg; authors declared no competing interests.
## Clinical Analysis & Structured Key Points
Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1 | medRxiv Skip to main content Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1 Karl Xaver Knaup , Karen Schneider , Hannah Schwarz , Rene Krueger , Andrea Wenzel , Florian Erger , Charlotte Sachse , Ursula Schloetzer-Schrehardt , Maike Buettner-Herold , Sonja Rehrl , Mario Schiffer , Bruno Huettel , Bodo Beck , Kathrin Skoczynski , Bjoern Buchholz , Francesca Pasutto , Johannes Schoedel , Michael Sean Wiesener doi: https://doi.org/10.64898/2026.09.16.26363125 Karl Xaver Knaup 1 Friedrich-Alexander University Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Karen Schneider 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hannah Schwarz 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rene Krueger 3 RWTH AachenUniversity Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrea Wenzel 4 University Hospital of Cologne; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Florian Erger 5 University Medicine Greifswald; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Charlotte Sachse 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ursula Schloetzer-Schrehardt 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maike Buettner-Herold 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sonja Rehrl 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mario Schiffer 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bruno Huettel 6 Max Planck Institute for Plant Breeding Research, Cologne; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bodo Beck 4 University Hospital of Cologne; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kathrin Skoczynski 7 University of Regensburg Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bjoern Buchholz 7 University of Regensburg Find this author on Google Scholar Find this author on PubMed Search for this author on this site Francesca Pasutto 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Johannes Schoedel 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael Sean Wiesener 2 Friedrich-Alexander Universitaet Erlangen-Nuernberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: michael.wiesener{at}uk-erlangen.de Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a genetically heterogeneous group of diseases that regularly lead to kidney failure in mid adulthood. In ADTKD-MUC1 a distinct neoprotein generated by a frameshift mutation, MUC1-fs, is pathogenic and accumulates in distal renal tubular cells. However, the pathomechanism of the disease and the regulation of the MUC1-fs are poorly understood. Primary tubular cells from the urine of several probands were established and immortalized. The length of the repeat region of both alleles of MUC1, as well as the mutated repeat localization were precisely defined by long range sequencing. The pathogenic MUC1-fs is readily detectable in patient-derived cells and has a considerably longer half-life than the wild-type mucin 1. Targeting the secretory pathway with BRD4780, a compound previously reported as putatively therapeutic, leads to downregulation of MUC1-fs in each of our patient-derived cell model. However, wild-type mucin 1 and numerous other transcriptional pathways were also affected by BRD4780, thus being rather unselective. Tubular cells derived from the urine appear to be a suitable model to analyze the pathogenic MUC1-fs of an individual patient, enabling pharmacological studies of novel therapies. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of the Friedrich-Alexander University Erlangen-Nuernberg, Germany, gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data generated for this project have been deposited in the GEO database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE306788. All other data that support the findings of this study are available in the Materials and Methods, Results, and/or Supplemental Material of this article. https://www.ncbi.nlm.nih.gov/geo/ Funder Information Declared Deutsche Forschungsgemeinschaft, https://ror.org/018mejw64 , Projektnummer 509149993, TRR 374, Project C4 , Projektnummer 509149993, TRR 374, Project C5 , Projektnummer 509149993, TRR 374, Project A2 , Projektnummer 509149993, TRR 374, Project C2 ADTKD-NET of the European Joint Programme on Rare Diseases , EJP RD JTC 2023, EU Grant Agreement No. 825575 Bundesministerium fuer Bildung und Forschung (BMBF) , 01GM2402B Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Posted September 16, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1 Karl Xaver Knaup , Karen Schneider , Hannah Schwarz , Rene Krueger , Andrea Wenzel , Florian Erger , Charlotte Sachse , Ursula Schloetzer-Schrehardt , Maike Buettner-Herold , Sonja Rehrl , Mario Schiffer , Bruno Huettel , Bodo Beck , Kathrin Skoczynski , Bjoern Buchholz , Francesca Pasutto , Johannes Schoedel , Michael Sean Wiesener medRxiv 2026.09.16.26363125; doi: https://doi.org/10.64898/2026.09.16.26363125 Share This Article: Copy Citation Tools Characterization of the neoprotein MUC1-fs in patient-derived cells with ADTKD-MUC1 Karl Xaver Knaup , Karen Schneider , Hannah Schwarz , Rene Krueger , Andrea Wenzel , Florian Erger , Charlotte Sachse , Ursula Schloetzer-Schrehardt , Maike Buettner-Herold , Sonja Rehrl , Mario Schiffer , Bruno Huettel , Bodo Beck , Kathrin Skoczynski , Bjoern Buchholz , Francesca Pasutto , Johannes Schoedel , Michael Sean Wiesener medRxiv 2026.09.16.26363125; doi: https://doi.org/10.64898/2026.09.16.26363125 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (902) Anesthesia (333) Cardiovascular Medicine (4819) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1629) Epidemiology (15955) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7051) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5051) Health Policy (1435) Health Systems and Quality Improvement (1768) Hematology (585) HIV/AIDS (1345) Infectious Diseases (except HIV/AIDS) (16296) Intensive Care and Critical Care Medicine (1173) Medical Education (669) Medical Ethics (155) Nephrology (724) Neurology (7278) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3611) Ophthalmology (1053) Orthopedics (398) Otolaryngology (457) Pain Medicine (470) Palliative Medicine (139) Pathology (709) Pediatrics (1800) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5905) Public and Global Health (9762) Radiology and Imaging (2427) Rehabilitation Medicine and Physical Therapy (1453) Respiratory Medicine (1249) Rheumatology (641) Sexual and Reproductive Health (772) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Blood urea nitrogen–to–albumin ratio (BAR) and kidney stones: cross-sectional NHANES analysis](https://medichelpline.com/clinical-feed/medrxiv-4-association-between-blood-urea-nitrogen-to-albumin-ratio-and-kidney-stones-a.md)
- [Hepatitis E Virus IgG Seropositivity and Kidney Dysfunction in US Adults](https://medichelpline.com/clinical-feed/medrxiv-3-hepatitis-e-virus-immunoglobulin-g-seropositivity-and-kidney-dysfunction-among.md)
- [Barriers to Primary Healthcare for the Rural Bangladeshi Elderly: A Social Ecological Model Review](https://medichelpline.com/clinical-feed/plos-one-19-using-the-social-ecological-model-to-identify-barriers-to-accessing-and-using.md)
- [Understanding Parasitic Identification in Delusional Parasitosis](https://medichelpline.com/clinical-feed/plos-one-21-bridging-perception-and-reality-parasitic-identification-in-delusional.md)
- [Fish oil plus metformin for vascular and cardiac health in women with PMOS: protocol for a randomi](https://medichelpline.com/clinical-feed/bmj-open-6-effect-of-fish-oil-as-an-adjunct-therapy-to-metformin-on-vascular-and-cardiac.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.